PT828495E - Dispersoes solidas estabilizadas de misoprostol - Google Patents

Dispersoes solidas estabilizadas de misoprostol

Info

Publication number
PT828495E
PT828495E PT96914641T PT96914641T PT828495E PT 828495 E PT828495 E PT 828495E PT 96914641 T PT96914641 T PT 96914641T PT 96914641 T PT96914641 T PT 96914641T PT 828495 E PT828495 E PT 828495E
Authority
PT
Portugal
Prior art keywords
cellulose
excipients
misoprostol
beta
hydroxypropyl
Prior art date
Application number
PT96914641T
Other languages
English (en)
Inventor
James E Truelove
Tugrul T Kararli
David Otto
Stanley C Penzotti Jr
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PT828495E publication Critical patent/PT828495E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT96914641T 1995-06-01 1996-05-22 Dispersoes solidas estabilizadas de misoprostol PT828495E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45791495A 1995-06-01 1995-06-01

Publications (1)

Publication Number Publication Date
PT828495E true PT828495E (pt) 2003-01-31

Family

ID=23818570

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96914641T PT828495E (pt) 1995-06-01 1996-05-22 Dispersoes solidas estabilizadas de misoprostol

Country Status (13)

Country Link
US (1) US5935939A (pt)
EP (1) EP0828495B1 (pt)
JP (1) JPH11506100A (pt)
AT (1) ATE226826T1 (pt)
AU (1) AU5794196A (pt)
CA (1) CA2222811C (pt)
DE (1) DE69624564T2 (pt)
DK (1) DK0828495T3 (pt)
ES (1) ES2185773T3 (pt)
PT (1) PT828495E (pt)
TW (1) TW434029B (pt)
WO (1) WO1996038153A1 (pt)
ZA (1) ZA964482B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0952821A4 (en) * 1996-12-31 2006-07-26 Nektar Therapeutics METHODS FOR DRYING AQUEOUS SUSPENSION OF HYDROPHOBIC DRUGS WITH HYDROPHILIC EXCIPIENTS AND COMPOSITIONS PREPARED THEREFROM
EP0896823B1 (en) * 1997-07-15 2002-09-25 Development Center For Biotechnology Improved stabilization of Misoprostol
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
CA2241342C (en) * 1998-06-15 2000-02-08 Bernard Charles Sherman Pharmaceutical tablets comprising an nsaid and a prostaglandin
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
ATE444060T1 (de) * 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
AU2003283769A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
BR0317593A (pt) * 2002-12-20 2005-11-22 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase
SG135204A1 (en) 2003-07-18 2007-09-28 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060286172A1 (en) * 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
WO2007035954A2 (en) * 2005-09-23 2007-03-29 Duramed Pharmaceuticals, Inc. Vaginal tablets comprising misoprostol and methods of making and using the same
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
WO2007146795A2 (en) * 2006-06-12 2007-12-21 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
TWI508753B (zh) * 2012-02-03 2015-11-21 Ono Pharmaceutical Co For the manufacture of beta-cyclodextrin (LIMAPROST) preparations
JP6524744B2 (ja) * 2014-03-25 2019-06-05 三菱ケミカルフーズ株式会社 難水溶性物質含有固体分散体の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
DE2515001C2 (de) * 1975-04-04 1986-10-02 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandin enthaltende gefriergetrocknete Pulver
SE431821B (sv) * 1979-01-29 1984-03-05 Perstorp Ab Lagringsstabilt, prostaglandininnehallande medicinskt preparat
US4211793A (en) * 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
US4301146A (en) * 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
US4335097A (en) * 1981-01-15 1982-06-15 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and process for the preparation thereof
US4431833A (en) * 1982-12-27 1984-02-14 American Cyanamid Company Prostaglandin and hydroxylated fatty acid ester formulations
DE3346525A1 (de) * 1983-12-22 1985-07-04 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich
JPH03220201A (ja) * 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体

Also Published As

Publication number Publication date
CA2222811A1 (en) 1996-12-05
ES2185773T3 (es) 2003-05-01
EP0828495B1 (en) 2002-10-30
JPH11506100A (ja) 1999-06-02
EP0828495A1 (en) 1998-03-18
AU5794196A (en) 1996-12-18
ZA964482B (en) 1997-02-06
DE69624564D1 (de) 2002-12-05
WO1996038153A1 (en) 1996-12-05
DK0828495T3 (da) 2003-02-24
US5935939A (en) 1999-08-10
DE69624564T2 (de) 2003-03-20
ATE226826T1 (de) 2002-11-15
CA2222811C (en) 2008-09-30
TW434029B (en) 2001-05-16

Similar Documents

Publication Publication Date Title
PT828495E (pt) Dispersoes solidas estabilizadas de misoprostol
AU8090791A (en) Aminosteroids for ophthalmic use
ES2094781T3 (es) Composicion farmaceutica de microparticulas con liberacion controlada y su proceso de preparacion.
MX2022015379A (es) Copolimeros de injerto de dextrano-alfa-glucano y derivados de estos.
ATE540697T1 (de) Stabilisiertes synthetisches immunogen- abgabesystem
HUP0301302A2 (en) Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and process for its manufacture
BG104534A (en) Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
HK1004119A1 (en) Cross-linked polymers made from 1,3,7-octatriene and like conjugated polyenes
WO1998040069A3 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
AU2003258205A1 (en) Active agent delivery system including a hydrophobic cellulose derivate
AU8679198A (en) Modified polylactide compositions, water-responsive, biodegradable films and fibers comprising polylactide and poly(vinyl alcohol) and methods for making the same
BR9813118A (pt) Uso de nanofibrilas de celulose essencialmente amorfas, e, formulação cosmética
MX2007002692A (es) Poligalactomanano cationico de alto grado de sustitucion para productos de cuidado de la piel.
NO985978L (no) Insulinpreparater som inneholder karbohydrater
WO2002002189A3 (en) Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
ES2142432T3 (es) Forma de dosificacion de la gepirona.
DK0404582T3 (da) Gellangummilim
RU93035980A (ru) Средство для лечения ран и оказания первой медицинской помощи
AU4555993A (en) Cross-linked polyhydroxylic material for enzymatically controlled drug release
AU4302099A (en) Knee prosthesis
FR2736056B1 (fr) Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
AU7670600A (en) Crosslinked copolymers based on non-crosslinked polycarboxylic copolymers
USD434878S (en) Elbow and knee protector
ATE364403T1 (de) Retardtablette hergestellt aus linearen wasserunlöslichen polysacchariden
WO1997034932A3 (en) Compositions containing starch excipients